HC Wainwright Estimates Editas Medicine Q1 Earnings

Editas Medicine, Inc. (NASDAQ:EDIT) – Investment analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Editas Medicine in a report released on Monday, April 28th. HC Wainwright analyst M. Kapoor forecasts that the company will post earnings of ($0.55) per share for the quarter. HC Wainwright currently has a “Strong-Buy” rating and a $3.00 price target on the stock. The consensus estimate for Editas Medicine’s current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Editas Medicine’s Q2 2025 earnings at ($0.33) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($1.50) EPS, Q1 2026 earnings at ($0.45) EPS, Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.48) EPS, Q4 2026 earnings at ($0.18) EPS and FY2026 earnings at ($1.49) EPS.

Editas Medicine (NASDAQ:EDIT) last posted its quarterly earnings data on Wednesday, March 5th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.16). Editas Medicine had a negative return on equity of 80.13% and a negative net margin of 340.96%. The business had revenue of $30.60 million for the quarter, compared to analyst estimates of $37.17 million. During the same period in the prior year, the firm posted ($0.23) EPS.

Separately, Cantor Fitzgerald upgraded Editas Medicine from a “hold” rating to a “strong-buy” rating in a research note on Tuesday. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating, three have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, Editas Medicine has an average rating of “Hold” and an average price target of $6.54.

Editas Medicine Stock Down 1.8 %

Shares of EDIT opened at $1.62 on Thursday. Editas Medicine has a 12-month low of $0.91 and a 12-month high of $6.69. The firm has a market capitalization of $135.61 million, a price-to-earnings ratio of -0.63 and a beta of 2.16. The stock’s 50-day moving average price is $1.42 and its 200 day moving average price is $1.80.

Institutional Investors Weigh In On Editas Medicine

Large investors have recently modified their holdings of the stock. Invesco Ltd. increased its position in Editas Medicine by 9.2% in the fourth quarter. Invesco Ltd. now owns 100,164 shares of the company’s stock worth $127,000 after purchasing an additional 8,448 shares during the period. Allspring Global Investments Holdings LLC increased its position in Editas Medicine by 45.9% in the first quarter. Allspring Global Investments Holdings LLC now owns 35,781 shares of the company’s stock worth $40,000 after purchasing an additional 11,252 shares during the period. Intech Investment Management LLC increased its position in Editas Medicine by 43.1% in the fourth quarter. Intech Investment Management LLC now owns 40,942 shares of the company’s stock worth $52,000 after purchasing an additional 12,336 shares during the period. Dark Forest Capital Management LP increased its position in Editas Medicine by 66.9% in the fourth quarter. Dark Forest Capital Management LP now owns 32,787 shares of the company’s stock worth $42,000 after purchasing an additional 13,138 shares during the period. Finally, JPMorgan Chase & Co. increased its position in Editas Medicine by 2.1% in the fourth quarter. JPMorgan Chase & Co. now owns 787,599 shares of the company’s stock worth $1,000,000 after purchasing an additional 16,419 shares during the period. 71.90% of the stock is currently owned by institutional investors.

Editas Medicine Company Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.